Mounjaro Maker Eli Lilly Improves In Quality As BofA Sees 'Room For Stock Upside' With $3 Billion In Sales By 2026

Core Insights - Eli Lilly and Co. has improved its quality score, moving into the top decile of Benzinga Edge's Stock Rankings, indicating strong fundamental strength and operational efficiency [1][2] - Bank of America has issued a bullish note, suggesting that the market is underestimating Eli Lilly's dominance in the obesity sector, particularly with its upcoming products [1][5] Group 1: Quality and Performance Metrics - Eli Lilly's quality score increased from 89.66 to 90.04, placing it in the elite tier above 90% of its peers [2] - The company boasts a near-perfect growth score of 99.38, reflecting a combination of rapid expansion and operational stability [3] Group 2: Analyst Insights and Future Potential - Analyst Jason Gerberry from Bank of America reiterated a Buy rating, emphasizing that Eli Lilly's long-term value is not fully reflected in its current stock price [5] - There is potential for stock upside as Eli Lilly continues to launch key obesity treatments and mitigate risks associated with new therapies [6] Group 3: Product Pipeline and Revenue Forecasts - The anticipated launch of Orforglipron, an oral weight-loss pill, is projected to generate $3 billion in revenue by 2026, significantly higher than the consensus estimate of $1 billion [6] - Positive Phase 3 trial results for Orforglipron indicate its effectiveness in helping patients maintain weight loss, thereby de-risking future revenue streams for the company [7] Group 4: Stock Performance - Eli Lilly's stock was up 0.10% in premarket trading after closing 1.45% higher at $1,056.88, with a year-to-date increase of 35.83% and a 38.57% rise over the last six months [8]